News
Kamada Meets "Primary Endpoint" in AAT Phase III Trial
NESS ZIONA, Israel—Kamada, a biopharmaceutical company developing, producing and marketing a line of specialty, life-saving therapeutics, announced today that it has successfully met the primary endpoint in the Phase III US clinical trials with its intravenous Alpha-1 Antitrypsin (AAT). The product is used to treat hereditary AAT deficiency which leads to Congenital Emphysema.
The “primary endpoint” is the main result measured at the end of a study to see if a given treatment worked.
David Tsur, Chief Executive Officer of Kamada, commented, “It is a major achievement for Kamada toward the future entry to US market, that further demonstrates the quality of our products and capabilities for the benefit of AAT deficient patients worldwide. The company’s intravenous AAT is the only ready-to-use AAT product that does not require reconstitution before use. Concurrently, Kamada is developing the next generation AAT for various indications, to be delivered by inhalation, directly to the lungs.”
